Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lung Neoplasms 84Prostatic Neoplasms 73Leukemia, Myeloid, Acute 73Carcinoma, Non-Small-Cell Lung 61Neoplasm Metastasis 60Breast Neoplasms 56Multiple Myeloma 47Colorectal Neoplasms 47Pancreatic Neoplasms 43Melanoma 36Carcinoma, Renal Cell 36Myelodysplastic Syndromes 35Ovarian Neoplasms 33Leukemia, Lymphocytic, Chronic, B-Cell 30Triple Negative Breast Neoplasms 28Glioblastoma 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 25Lymphoma 23Squamous Cell Carcinoma of Head and Neck 22Burkitt Lymphoma 22Fallopian Tube Neoplasms 21Glioma 20Carcinoma, Hepatocellular 20Brain Neoplasms 18Mouth Neoplasms 17Lymphoma, Non-Hodgkin 17Leukemia, Biphenotypic, Acute 17Endometrial Neoplasms 17

Interventions

Hysterectomy 2ipatasertib 1entinostat 1Telemedicine 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Ovariectomy 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1Interviews as Topic 1Health Promotion 1Exercise Test 1Educational Status 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Specimen Handling × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡